Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Total Non-current Liabilities
All obligations due after more than one year.
Damora Therapeutics, Inc.NASDAQ: DMRA
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 6.6% from a year ago
Total non-current liabilities stood at $1.37M at the end of Q1 FY2026, down 6.6% from a year earlier and up 1588.9% from the prior quarter. Over 3 fiscal years it compounded at -37.3% a year.
Context
- Total non-current liabilities amounted to 0.3% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 81K USD
- Year-over-year change
- -94.5%
- 4-year CAGR
- -34.8%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81K | -94.5% |
| FY2024 | 2024-12-31 | 1.46M | +2118.2% |
| FY2023 | 2023-12-31 | 66K | -79.9% |
| FY2022 | 2022-12-31 | 328K | -26.8% |
| FY2021 | 2021-12-31 | 448K | — |
Total Non-current Liabilities vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's Mar 2026 total non-current liabilities of $1.37M is the 8th highest of the 9 companies compared; the peer median is $138.5M.
- Its year-over-year change of -6.6% is the 5th highest of 8, against a peer median of +0.1%.
- Total non-current liabilities amounts to 0.3% of total assets for DMRA, versus a peer median of 6.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.42B | +916.7% | +76.6% | 43.3% | |
| Mar 2026 | $570.17M | +6.5% | +54.4% | 73.2% | |
| Mar 2026 | $231.44M | +0.1% | +90.2% | 43.3% | |
| Jun 2026 | $216.12M | -41.9% | -2.8% | 2.7% | |
IRONDisc Medicine, Inc. | Sep 2026 | $60.88M | +100.8% | +209.4% | 8.7% |
| Mar 2026 | $15.22M | -83.2% | -34.8% | 3.0% | |
| Mar 2026 | $13.81M | -15.3% | +4.2% | 4.4% | |
DMRADamora Therapeutics, Inc. | Mar 2026 | $1.37M | -6.6% | -37.3% | 0.3% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $566K | — | — | 0.1% |
| Peer median (excluding DMRA) | $138.5M | +0.1% | +54.4% | 6.6% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62.56M | 32.79M | 21.47M | 14.18M | 257.62M |
| Short-term Investments | 37.63M | 27.44M | 11.69M | 0 | 0 |
| Net Receivables | 2.28M | 1.38M | 1.72M | 881K | 899K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.9M | 1.5M | 1.13M | 1.19M | 1.32M |
| Total Current Assets | 110.1M | 63.91M | 36.77M | 16.84M | 260.42M |
| Property, Plant & Equipment (Net) | 1.04M | 1.17M | 325K | 130K | 104K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 9.05M | 5.83M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.03M | 2.28M | 1.13M | 163K | 0 |
| Total Non-current Assets | 12.11M | 9.28M | 1.45M | 293K | 104K |
| Total Assets | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Account Payables | 1.53M | 3.35M | 1.7M | 377K | 444K |
| Short-term Debt | 399K | 476K | 183K | 12K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.01M | 6.68M | 2.96M | 604K | 1.52M |
| Total Current Liabilities | 4.54M | 11.11M | 5.83M | 1.2M | 20.07M |
| Long-term Debt | 0 | 0 | 0 | 1.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 43K | 28K |
| Total Non-current Liabilities | 448K | 328K | 66K | 1.46M | 81K |
| Total Liabilities | 4.99M | 11.44M | 5.9M | 2.66M | 20.15M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (156.11M) | (217.74M) | (256.08M) | (277.52M) | (487.36M) |
| Accumulated OCI | (320K) | (244K) | 380K | 97K | 802K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.22M | 61.75M | 32.33M | 14.47M | 240.38M |
| Total Debt | 847K | 804K | 249K | 1.43M | 68K |
| Net Debt | (61.72M) | (31.98M) | (21.22M) | (12.74M) | (257.56M) |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.